TOP TRENDING

Pfizer claims the coronavirus vaccine is 90% effective in clinical trials


The UK could get 10 million doses of coroanvirus vaccine by Christmas and be back to "normal" by the spring, after a leading candidate is shown to be 90 percent effective.

Stock markets around the world rose sharply this morning as Pfizer and BioNTech announced early results from a massive clinical study that found nine out of ten people who received their bump would be protected from it.

The FTSE 100 index is on its way to its best day since March. The shares in airlines and hotel companies are increasing.

Boris Johnson will hold a press conference at 5 p.m. to update the public on the optimistic news.

The prime minister's spokesman warned that there were "no guarantees" but said the results were "promising" and maintained the prospect that if approved, millions of doses of the vaccine could be in circulation by Christmas.

"In total, we have sourced 40 million doses of the Pfizer candidate vaccine, 10 million of which will be manufactured by the end of the year and available to the UK if the vaccine is approved by regulators," the spokesman said.

Professor Sir John Bell, a member of the government's vaccine task force, said he was "confident" that life would be back to normal by spring. & # 39; yes yes yes yes. I'll probably be the first to say this, but I will say this with some confidence, ”he told BBC Radio 4's World at One.

The company's chairman hailed the breakthrough as a "big day for science" while independent experts said the results were "excellent" and "really impressive".

Pfizer and BioNTech are expected to apply for approval to have the engraving in the US as soon as possible. However, you will have to wait for the long-term security data to be complete.

The vaccine is one of at least seven vaccines that have already been pre-ordered by the UK. The push must be given in two installments so that in theory five million people can get it from the pre-Christmas batch.

On another dramatic day of coronavirus developments:

  • Donald Trump's supporters questioned the timing of the announcement, less than a week after the razor-sharp elections brought Joe Biden to victory. Mr Trump, who is still denying the outcome, tweeted that it was "good news";
  • Tories are calling for the blanket lockdown in England to end before December 2, amid allegations that Boris Johnson felt he was dragged into the move by cabinet leaks and inflated dates.
  • Wales has ended its own "fire break" lockdown, stating that the cases are apparently falling, but First Secretary Mark Drakeford has told people not to hand-deliver Christmas cards this year.

A volunteer in a vaccine study in Turkey will receive a dose of Pfizer and BioNTech in late October. The study is still ongoing and has enrolled more than 43,000 people around the world

Pfizer and BioNTech have produced one of the world's leading candidates for a coronavirus vaccine and are the first to publish the results of their final study

Pfizer and BioNTech have produced one of the world's leading candidates for a coronavirus vaccine and are the first to publish the results of their final study

Boris Johnson (pictured today in Westminster) will hold a press conference at 5pm to break the news of the optimistic news

Boris Johnson (pictured today in Westminster) will hold a press conference at 5 p.m. to break the news of the optimistic news

Donald Trump's supporters questioned the timing of the announcement, less than a week after the razor-sharp elections brought Joe Biden to victory. Mr Trump, who is still denying the outcome, tweeted that it was "great news".

Donald Trump's supporters questioned the timing of the announcement, less than a week after the razor-sharp elections brought Joe Biden to victory. Mr Trump, who is still denying the outcome, tweeted that it was "great news".

STOCK MARKETS RISE ON VACCINE HOP

Global stock markets hoped for an end to the coronavirus crisis today after vaccine news was released.

In the US, which was already at a high after the elections gave a clear result, the Dow futures rose 4.2 percent and the S&P 500 rose 3.1 percent.

Pfizer shares, listed in New York, rose more than 10 percent in pre-market trading.

The FTSE 100 index rose by more than 4.5 percent compared to the successful studies.

The UK's FTSE index rose nearly five percent on the news, its highest level since August

The UK's FTSE index rose nearly five percent on the news, its highest level since August

This was the highest level since mid-August, while other markets around the world also recorded strong growth.

The IAG airline group grew 35 percent, while Rolls Royce saw a 30 percent increase.

Movie theater and hotel chains also received a massive boost as investors digested the bullish signs.

In Europe, the French CAC 40 rose 5.6 percent to 5,239, while the German DAX rose 5.1 percent to 13,112.

Pfizer and the German partner BioNTech are the first drug manufacturers to show successful data from a large-scale clinical trial with a coronavirus vaccine.

They said 94 people in a study of more than 43,000 people have tested positive for Covid-19 to date and that over 90 percent of those polled didn't get a real vaccine.

You were in the placebo group where people are given a fake vaccine so what happens to them can be compared to those who get the real thing. Pfizer's study split the participants half into placebo and half vaccine groups.

Companies haven't released the exact number, but a 90 percent effectiveness rate suggests that no more than eight people who received the vaccine infected the virus, compared to 86 people who received a fake sting.

Your next step is expected to be in the US to apply for an emergency permit, which they'll need to contact the Food & Drug Administration for once they have two months of safety data – which is expected to be completed by the end of this month .

If approved in the US, the UK could soon follow suit.

Kate Bingham, head of the UK's Coronavirus Vaccines Task Force, said earlier this month that 10 million doses of Pfizer's shock could be available in the UK by January.

In an interview with CNBC today, Pfizer Chairman and CEO Albert Bourla welcomed "Light at the end of the tunnel".

"The hopes of billions of people and millions of businesses and hundreds of governments that have been felt on our shoulders, now we can see light at the end of the tunnel," he said.

The cans will be phased in and production will increase "significantly" by the middle of next year.

& # 39; We started manufacturing some time ago. We believe we will have 50 million this year and 1.3 billion next year. This will come gradually; less in the beginning, then more in the first quarter, more in the second quarter, and then we will see a significant increase in the second half of the year.

& # 39; Given how effective it is, we understand that demand will be much higher than anything we can produce.

& # 39; We are currently also thinking outside the box as to whether there are other ways to increase production capacity even further. Currently, 1,000 people die every day in the United States. There is no time to waste here. & # 39;

Mr Bourla went on to say that he hopes other drug companies will be just as effective with their own vaccines and that "the only competitor is virus and time".

Scientists said today's news marks a breakthrough in the global race to develop a sting to stop the pandemic.

Sir John Bell, Regius Professor of Medicine at Oxford University and a member of the government's vaccine task force, said other vaccines are expected to be available in the near future.

“I am very pleased with this result – it shows that you can make a vaccine against this small animal. Ninety percent is an amazing level of effectiveness, ”he told BBC Radio 4's The World at One.

Tories is pushing for an early end to the lockdown amid allegations that PM is angry about being "thrown back".

Tories is pushing for an end to the blanket lockdown before December 2 after Boris Johnson claims he hit the extreme curbs.

Senior MPs said the prime minister shouldn't keep the restrictions on for the entire month just to maximize the pain, given the first signs that the surge is already leveling off.

Mr Johnson reluctantly signed the measures for England last weekend after warnings by government scientists that the death toll could rise to 4,000 a day – four times as high as in April.

The decision was taken with minimal Cabinet consultation following news of the warning, and the Prime Minister's response to it was relayed to news outlets, including the Daily Mail.

However, the number of 4,000 a day has since been largely discredited, and government scientists have been forced to correct other dire warnings used to inform the lockdown decision.

Some data from last week suggests that the second wave may have flattened or even peaked before the lockdown was introduced last Thursday.

An additional 156 deaths from Covid were reported across the UK yesterday, up from 162 a week ago.

Around 20,572 cases have been registered, down from 2,682 from 23,254 last Sunday.

"It's the cornerstone of other vaccines because now I see no reason why we shouldn't have a handful of good vaccines."

Dr. Paul Hunter, a medical and infectious disease expert at the University of East Anglia, told MailOnline, “If it finally holds up, that's a remarkably good result.

“It's always a big question, of course, how long it will take. You may need to recharge every year, we don't know. It could all get pear-shaped.

"Provided we get this vaccine and it arrives as planned, it will make a huge difference in a matter of months."

When asked if the push could still fail despite promising early results, he added, “There is always a possibility. Most of the time, the final results will be the same as the intermediate results, but you cannot guarantee this.

“I am very happy about this result. You can almost start to see the light at the end of the tunnel. I just hope it's not an oncoming train. & # 39;

Scientists across the UK have said the results are cause for optimism but are still only early signs. It is therefore important not to get carried away.

Oxford University professor Peter Horby, who led the team that proved the steroid dexamethasone can save dying coronavirus patients, said: “This news made me smile from ear to ear.

& # 39; It's a relief to see such positive results with this vaccine, and it's a good sign for Covid-19 vaccines in general. Of course we have to see more details and wait for the final results, and there is still a long way to go before vaccines make a real difference, but that feels like a turning point to me. & # 39;

Professor Brendan Wren of the London School of Hygiene & Tropical Medicine said, “A 90 percent effectiveness for a phase 3 study is great for a new vaccine that could make a big difference, but there are more confirmatory safety and effectiveness studies required.

& # 39; The RNA-based vaccine requires two doses and its actual effectiveness over time has yet to be evaluated. These are encouraging results, and it's a case of so far so good. & # 39;

Professor Eleanor Riley, an immunology and infectious disease expert at the University of Edinburgh, added: “At first glance, this is exceptionally good news: a vaccine that is 90 percent effective in preventing symptomatic cases of Covid-19 and Includes millions of doses available by the end of the year.

“ However, the full dataset on which the claim is based has not yet been released so we don't know exactly what was found.

& # 39; The two companies are trying to point out that the study participants are ethnically different, which is good, but doesn't say anything about the ages of the people in the study. If a vaccine is to reduce serious illness and death, and thus enable the population to return to normal, it must be effective in older and older members of our society.

& # 39; We also don't yet know about the severity of the cases identified in the study, whether infection or infectivity was prevented, or how long immunity is likely to last.

"But I think we have reason to be cautiously optimistic."

Optimism was the stock market reaction when the news broke. The UK's FTSE was at its highest level since August, with some companies up more than a third.

In the US, which was already at a high after the elections gave a clear result, the Dow futures rose 4.2 percent and the S&P 500 rose 3.1 percent.

Pfizer shares, listed in New York, gained more than 10 percent in pre-market trading. The company's listing on the French stock exchange rose 14 percent.

The FTSE 100 index rose more than 4.5 percent on the news. It was at its highest level since mid-August and on its way to its best day since March, while other markets around the world also saw strong gains.

The IAG airline group grew 35 percent, while Rolls Royce saw a 30 percent increase.

Movie theater and hotel chains also received a massive boost as investors digested the bullish signs.

In Europe, the French CAC 40 rose 5.6 percent to 5,239, while the German DAX rose 5.1 percent to 13,112.

Pfizer and BioNTech said they had not identified any serious safety concerns to date and expect to seek clearance for the US emergency later this month.

If allowed, the number of vaccine doses is initially limited. Many questions also remain, including how long the vaccine will be protected.

However, the news gives hope that other vaccines under development against the novel coronavirus may also prove effective.

"Today is a great day for science and humanity," Bourla said in a statement.

"We are reaching this critical milestone in our vaccine development program at a time when the world needs it most, as infection rates are breaking new records, hospitals are on the verge of overcapacity, and economies are struggling to reopen."

Pfizer expects to obtain full U.S. emergency approval for the vaccine for those ages 16 to 85.

For this purpose, two months of safety data must have been collected from around half of the around 44,000 participants in the study, which is expected to be completed by the end of November.

"I'm almost excited," said Dr. Bill Gruber, one of Pfizer's top vaccine scientists. "This is a great day for public health and the potential to bring us all out of the circumstances we are in now."

The effectiveness rate is well above the 50 percent effectiveness required by the US Food and Drug Administration for a coronavirus vaccine.

To confirm the rate of effectiveness, Pfizer said the study will continue until there are 164 Covid-19 cases among participants. Given the recent surge in US infection rates, that number could be hit in early December, said Dr. Gruber.

Pictured is the first patient to receive the Pfizer vaccine at the University of Maryland in May of this year. Since then, more than 43,000 people have been enrolled in the pioneering process

Pictured is the first patient to receive the Pfizer vaccine at the University of Maryland in May of this year. Since then, more than 43,000 people have been enrolled in the pioneering process

The data still has to be examined by experts or published in a medical journal. Pfizer said it would do so once the results of the entire trial were in.

Pfizer and BioNTech have signed a $ 1.95 billion (£ 1.45 million) contract with the US government to supply 100 million doses of vaccine starting this year. They also have supply agreements with the European Union, the UK, Canada and Japan.

To save time, companies started making the vaccine before they knew if it would be effective, and now expect to produce up to 50 million doses this year, or enough vaccine to protect 25 million people.

Pfizer expects to produce up to 1.3 billion doses of the vaccine by 2021.

The vaccine uses messenger RNA (mRNA) technology, which is based on synthetic genes that can be created and manufactured in weeks, and made on a larger scale than traditional vaccines.

Moderna Inc, whose vaccine candidate uses similar technology, is expected to release the results of its large-scale study later this month. MRNA technology was developed to trigger an immune response without using pathogens such as actual virus particles.

Pfizer alone will not be able to provide enough vaccines for the entire United States immediately. The Trump administration has announced that it will have enough supplies for every 330 million U.S. residents who want to be vaccinated by mid-2021.

Which vaccines are safe in the UK?

1. GlaxoSmithKline and Sanofi Pasteur: 60 million cans

The government announced on July 29 that it had signed a deal with pharmaceutical giants GlaxoSmithKline (GSK) and Sanofi Pasteur

If the vaccine proves successful, the UK could start vaccinating priority groups as early as the first half of next year, e.g. B. Frontline health and social workers and those at increased risk for coronavirus (BEIS) said.

Human clinical trials of the vaccine will begin in September, followed by a phase 3 trial in December.

The vaccine is based on the existing technology used to manufacture Sanofi's seasonal flu vaccine. Genetic material from the surface protein of the SARS-CoV-2 virus is inserted into insect cells – the basis of Sanofi's influenza product – and then injected to elicit an immune response in a human patient.

2. AstraZeneca (Manufacturing University of Oxford): 100 million

AstraZeneca, which works with Oxford University, is already making the experimental vaccine after a deal was closed on May 17th.

Professor Sarah Gilbert, who leads the Oxford team, is confident the push could be ready for the most vulnerable by the end of the year.

Their comments came after the results of the first phase, published July 20 in The Lancet, were encouraging.

The team genetically engineered a virus so that it looks like the coronavirus – it has the same spike proteins on the outside – but cannot cause infection inside a person. This genetically-weakened virus is a type of virus called adenovirus, just like the ones that cause colds and were taken from chimps.

3. BioNTech / Pfizer: 30 million

The US drug giant Pfizer – known for the manufacture of Viagra – and the German company BioNTech signed a contract with the British government on July 20th.

Positive results were reported from the ongoing Phase 2/3 clinical trial, named BNT162b1, on July 1. The company is currently conducting phase 2 studies.

Pfizer's vaccine is a so-called mRNA vaccine that does not inject pieces of virus directly into the body, but sends genetic material.

mRNA vaccines program the body to produce parts of the virus itself by injecting the body with a molecule that tells disease-fighting cells what to make. The immune system then learns how to fight it.

4. Valneva: 60 million

The government has given Valneva – whose vaccine is in preclinical development – an undisclosed amount of money to expand their factory in Livingston, Scotland.

While the government announced a 60 million dose deal on July 20, the company said it had in principle reached an agreement with the UK government to provide up to 100 million doses.

Valneva's sting is an inactivated whole virus vaccine, which means it injects a damaged version of the coronavirus into the body itself.

The virus has been destroyed in a way that makes it incapable of causing infection, but the body still recognizes it as a dangerous invader and therefore triggers an immune response that it can remember in the event of a true Covid-19 infection .

5. Janssen (Johnson & Johnson): 30 million

The government has agreed to buy 30 million doses of a vaccine made by Janssen if it works.

Officials have agreed to help the company develop the sting by helping to fund a global clinical trial. The first human trials with Janssen's sting began in mid-July and are being carried out in the United States and Belgium on adults over the age of 18.

The sting is called Ad26.COV2-S, recombinant, and is a type of sting called a recombinant vaccine against viral vectors.

Proteins that occur outside of the coronavirus are reproduced in a laboratory and then injected into the body to stimulate an immune response.

The ad part of the vaccine name means that an adenovirus – a virus best known to cause colds – is used as a vehicle for transporting coronavirus genetics into the body.

6. Novavax: 60 million

The UK has ordered 60 million doses of a vaccine being developed by US-based Novavax. It will help fund late-stage clinical trials in the UK and advance plans to manufacture the vaccine in the UK.

Novavax 'shock, named NVX-CoV2373, showed positive results in early clinical trials.

It produced an immune response in 100 percent of people who received it, the company said, and was safe and "generally well tolerated."

Novavax's candidate is also a recombinant vaccine and transports the spike proteins located on the outside of the coronavirus into the body to provoke the immune system.

7. Imperial College London: Unknown crowd

Scientists at Imperial College London are working on Britain's second hope for a stab. The candidate is slightly behind Oxford's vaccine in terms of progress through clinical trials, but is still a major player.

The UK government is believed to have agreed to buy the vaccine if it works, but details of a deal have not yet been released.

The Imperial shock is currently in the second phase of human trials after initial tests showed it is safe.

Imperial College London will attempt to provide genetic material (RNA) from the coronavirus that will program cells in the patient's body to restore the spike proteins. It transports the RNA in droplets of liquid that are injected into the bloodstream.

(tagsToTranslate) Dailymail (t) Nachrichten (t) Coronavirus Vaccine Research (t) Coronavirus